Hormones and breast cancer

Human Reproduction Update

Volumn 10, Issue 4, 2004, Pages 281-293

  Blamey, R ^a   Collins, J ^a   Crosignani, Pier Giorgio ^b   Diczfalusy, E ^a   Heinemann, L A J ^a   La Vecchia, C ^a   Reeves, G ^a   Smith, I E ^a   Trichopoulos, D ^a   Arisi, E ^a   Baird, D T ^a   Benagiano, G ^a   Frigerio, G C ^a   Glasier, A ^a   Schmidt Gollwitzer, K ^a   Skouby, S O ^a   Volpe, A ^a  

^a Università di Milano ^*

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Contraception; Epidemiology; Estrogen receptor; Menopause hormone treatment

Indexed keywords

ANASTROZOLE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HORMONE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; BREAST FEEDING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; ENDOCRINE SYSTEM; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FEMALE; GROUPS BY AGE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; MAMMARY GLAND; MENARCHE; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOPOROSIS; PREDICTION; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 3242884189     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmh025     Document Type: Review

References (86)

1. Adami H-O, Signorello LB and Trichopoulos D (1998) Towards an understanding of breast cancer etiology. In Adami H-O and Trichopoulos D (eds) Progress and Enigmas in Cancer Epidemiology, 8. Semin Cancer Biol, pp 255-262.
2. Ahlgren M, Sorensen T, Wohlfahrt J, Haflidadottir A, Holst C and Melbye M (2003) Birth weight and risk of breast cancer in a cohort of 106 504 women. Int J Cancer 107,997-1000.
3. Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB and Brinton LA (2002) Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 88,50-57.
4. American Institute for Cancer Research/World Cancer Research Fund (2002) Food, Nutrition and the Prevention of Breast Cancer: A Global Perspective. American Institute of Cancer Research, Washington, DC, pp 252-287.
5. Anderson TJ, Battersby S, King RJB et al. (1989) Oral contraceptive use influences resting breast proliferation. Hum Pathol 20,1139-1144.
6. ATAC Trialists Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359,2131-2139.
7. Barrett-Connor E, Grady D, Sashegyi A et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 87,847-857.
8. Beral V, Banks E, Reeves G and Appleby P (1999) Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4,191-215.
9. Beral V, Banks E and Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360,942-944.
10. Bernstein L and Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15,48-65.
11. Blanks RG, Moss SM, McGahan CE, Queen MJ and Babb PJ (2000) Effect of NHS Breast Screening Programme on mortality from breast cancer in England and Wales, 1990-9: comparison of observed with predicted mortality. Br Med J 321,665-669.
12. Breast Cancer Trialists Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351,1451-1467.
13. Breast Screening Frequency Trial Group (2002) The frequency of breast cancer screening: results from the UK CCCR randomised trial. Eur J Cancer 38,1458-1464.
14. Burkman RT (2002) Reproductive hormones and cancer Ovarian and colon cancer. Obstet Gynecol Clin N Am 29,527-540.
15. Chlebowski RT, Hendrix SL, Langer RD et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women; The Women's Health Initiative Randomized Trial. J Am Med Assoc 289,3243-3253.
16. Clamp A, Danson S and Clemons M (2002) Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol 3,611-619.
17. Clemon M and Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344,276-285.
18. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332,1589-1593.
19. Collaborative Group on Hormonal Factors in Breast Cancer (1996a) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347,1713-1727.
20. Collaborative Group on Hormonal Factors in Breast Cancer (1996b) Breast cancer and hormonal contraceptives: further results. Contraception 54,1S-106S.
21. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative re-analysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 360,187-195.
22. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350,1047-1059.
23. Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 281,2189-2197.
24. Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA et al. (2001) Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 59,247-255.
25. Delmas PD, Bjarnason NH, Mitlak BH et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337,1641-1647.
26. Diczfalusy E (2002) Contraception and Society. Eur J Contracept Reprod Health Care 7,199-209.
27. Dumeaux V, Alsaker E and Lund E (2003) Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 105,844-850.
28. El-Ashry D and Lippman ME (1994) Molecular biology of breast carcinoma. World J Surg 18,12-20.
29. Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94,606-616.
30. Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene; results from a 3 year randomized clinical trial. J Am Med Assoc 282,637-645.
31. ESHRE Capri Workshop Group (2002) Hormonal Contraception: What is New? Human Reprod Update 8,359-371.
32. Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90,1371-1388.
33. Foidart JM, Colin C, Denoo X et al. (1998) Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69,963-969.
34. Friedenson B and Friedenson H (2002) Genetic testing for breast and ovarian cancer for women with a family history of breast cancer: weighing conflicting evidence about oral contraceptives. Med Gen Med 4,3.
35. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS and Sellers TA (2000) Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. J Am Med Assoc 284,1837-1838.
36. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC and Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95,30-37.
37. Grodstein F, Newcomb PA and Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106,574-582.
38. Hankinson S and Hunter D (2002) Breast cancer. In Adami HO, Hunter D, and Trichopoulos D (eds) Textbook of Cancer Epidemiology. Oxford University Press, New York, pp 301-339.
39. Henderson BE and Bernstein L (1996) Endogeneous and exogeneous hormone factors. In Harris JR, Lippman ME, Morrow M, and Hellman S (eds) Disease of the Breast. Lippincott-Raven, Philadelphia, PA, pp 185-200.
40. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA and Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84,4559-4565.
41. Hulley S, Furberg CD, Barrett-Connor E, Cauley J, Grady D, Haskell WL, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E and Hunninghake D (2002) Noncardiovascular disease outcomes during 68 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). J Am Med Assoc 288,58-66.
42. IBIS Working Party and Principal Investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 360,817-824.
43. International Agency for Research on Cancer (2003) The World Cancer Report. IARC, Lyon.
44. Jordan VC (2001) Selective estrogen receptor modulation: a personal perspective. Cancer Res 61,5683-5687.
45. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF and Blamey RW (1999) The prognosis of small primary breast cancers. Eur J Cancer 35,908-912.
46. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO and Lund E (2002) Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 11,1375-1381.
47. La Vecchia C, Brinton LA and McTiernan A (2001) Menopause, hormone replacement therapy and cancer. Maturitas 39,97-115.
48. La Vecchia C and Franceschi S (2003) Hormone replacement therapy and cancer: an update. Eur J Cancer Prev 12,3-4.
49. Levi F, Te V-C, Randimbison L and La Vecchia C (2003) Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 107,164-165.
50. Li C, Malone KE, Porter PL et al. (2003) Relationship between long durations and different regiments of hormone therapy and risk of breast cancer. J Am Med Assoc 289,3254-3263.
51. Magnusson C, Baron JA, Correia N, Bergström R, Adami H-O and Persson I (1999) Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int J Cancer 81,339-344.
52. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL et al. (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346,2025-2032.
53. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362,419-427.
54. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M et al. (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94,1773-1779.
55. Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP and Greenberg ER (2003) Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 106,961-964.
56. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B and Rutqvist LE (2002) Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359, 909-919.
57. Oettel M, Elger W, Fuhrmann U, Habenicht U-F and Gräser T From the Progestins to Antiprogestins to Progesterone Receptor Modulators - The Endocrine-Pharmacological Point of View. Presented at the 10th World Congress on the Menopause, 10-14 June 2002, Berlin.
58. Porch JV, Lee I-M, Cook NR, Rexrode KM and Buring JE (2002) Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 13,847-854.
59. Potischman N and Troisi R (1999) In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 10,561-573.
60. Powles TJ, Hickish T, Kanis JA et al. (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14, 78-84.
61. Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ and Thun MJ (2001) Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 153,145-152.
62. Ross RK, Paganini-Hill A, Wan PC and Pike MC (2000) Effect of hormone replacement therapy on breast cancer risks: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92,328-332.
63. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L and Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 283,485-491.
64. Schairer C, Gail M, Byrne C, Rosenberger PS, Sturgeon S, Brinton LA and Hoover RN (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91,264-270.
65. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton LA and Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 283,485-491.
66. Schneider HPG (2000) General aspects of worldwide HRT use. In Kato J, Minaguchi H, and Nishino Y (eds) Hormone Replacement Therapy and Osteoporosis. Ernst Schering Research Foundation Workshop, Springer, Berlin, pp 1-28, Suppl 4.
67. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH and Folsom AR (1997) The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127,973-980.
68. WHIMS Investigators, Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S and Wactawski-Wende J (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. J Am Med Assoc 289,2651-2662.
69. Singletary SE (2003) Rating the risk factors for breast cancer. Ann Surg 237,474-482.
70. Smith IE and Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348,2431-2442.
71. WHO Collaborative Study of Neoplasia and Steroid Contraceptives, Stalsberg H, Thomas DB and Noonan EA (1989) Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Int J Cancer 44,399-409.
72. Thomas DB (1991) The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: the influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. Contraception 43,695-710.
73. United Nations Department of Public Information, World Contraceptive Use 2001. United Nations, New York, DEV/2392 POP/829.
74. United Nations, World Population prospects: the 2002 Revision Highlights. United Nations, New York, ESA/P/WP180, 26 February 2003.
75. Ursin G, London S, Yang D, Tseng CC, Pike MC, Bernstein L, Stanczyk FZ and Gentzschein E (2002) Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 72,139-143.
76. Verkooijen HM, Fioretta G, Vlastos G et al. (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104,778-781.
77. Vessey M, Painter R and Yeates D (2003) Mortality in relation to oral contraceptive use and cigarette smoking. Lancet, 362,9379,185-191.
78. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S and Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345,1243-1249.
79. Weiss LK, Burkman RT, Cushing-Haugen KL et al. (2002) Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 100,1148-1158.
80. Willis DB, Calle EE, Miracle-McMahill HL and Heath CW (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7,449-457.
81. Winer EP, Hudis C, Burstein HJ et al. (2002) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 20,3317-3327.
82. Wiseman RA (2000) Breast cancer hypothesis: a single cause for the majority of cases. J Epidemiol Community Health 54,851-858.
83. World Health Organization (2001) World Health Report 2001. In Mental Health: New Understanding, New Hope. World Health Organization, Geneva.
84. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (1988) Endometrial cancer and combined oral contraceptives. Int J Epidemiol 17,263-269.
85. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (1989) Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 18,538-545.
86. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial. J Am Med Assoc 288,321-333.